CME

Accreditation:This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of University of Florida College of Medicine and American Society of Breast Disease. The University of Florida College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit: The University of Florida College of Medicine designates this live activity for a maximum of 18.5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note: The maximum number of 18.5 AMA PRA Category 1 Credits™  includes 15.5 designated for the Symposium, and 3.0 for a Pre-Symposium Workshop.

Objectives: Upon completion of this course, participants should be able to:

  • Specify the course of events leading to the current progress in breast cancer diagnosis, therapy and follow­up management, particularly of high risk patients.
  • Discuss the most recent approach to management of ductal carcinoma in situ and to axilla.
  • Demonstrate the role of molecular targeted therapy in providing individualized chemotherapy.
  • Assess the contributions of multimodality breast cancer screening and imaging techniques and technologies, including mammography, ultrasonography and MRI.
  • Analyze the role of discovery of breast cancer genes and the value of stratification of patients to enroll into various risk reduction strategies.
  • Describe the principle of pre-surgical neoadjuvant chemotherapy in breast cancer patients.
  • Discuss the role of radiotherapy and chemotherapy in early and metastatic breast cancer.
  • Evaluate the new prognostic and predictive factors of genomic assays.
  • Recognize management strategies for metastatic breast disease as identified by audience response system during Tumor Conference session.
  • Describe different approaches of oncoplastic surgery in providing better cosmetic results in breast cancer patients.
  • Identify contributions of the National Accreditation Program for Breast Centers consortium to improving the quality of care and monitoring of outcomes for patients with breast disease.
  • Describe risk assessment and breast cancer susceptibility genes in breast cancer.
  •  Explain the process of navigating breast cancer patients through the continuum of care.
  • Outline the role, including timing, of fertility preservation for breast cancer patients
  • Describe the developing international viewpoints on the need to manage symptoms of breast cancer patients and survivors.
  • Identify emerging results from clinical trials and studies on susceptibility, genetics and biomarkers, chemoprevention, diagnostic, and targeted therapies for breast cancer.